Read 6 late-breaking updates from ERS Congress 2026 that clinicians managing respiratory disease should know.
|Videos|September 8, 2021
Lung Cancer Screening & Treatment: What Comes Next?
Author(s)HCP Live
The pulmonology and oncology expert panel returns for another discussion on lung cancer treatment challenges presented by the pandemic—and how the field can recover.
Advertisement
Advertisement
Related to this article
Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.
However, Connect Biopharma's phase 2 Seabreeze STAT Asthma trial's primary treatment-failure end point missed statistical significance.
Wechsler, of National Jewish Health discusses how oral STAT6 degraders like KT-621 could offer a mechanistically distinct treatment option.
Wechsler walks through verekitug's mechanism, VALIANT's design, key efficacy and safety findings, and what's next for TSLP-targeted asthma therapy.
Advertisement
Advertisement
Trending on HCPLive
1
ASH Issues New Ferritin Thresholds for Iron Deficiency Diagnosis
2
Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD
3
Dersimelagon Gains FDA Priority Review for EPP, XLP
4
FDA Approves Finerenone (Kerendia) for CKD and Type 1 Diabetes
5